Bank of America’s Adamas Pharmaceuticals ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-66,745
| Closed | -$328K | – | 9009 |
|
|
2021
Q3 | $328K | Buy |
66,745
+6,406
| +11% | +$31.1K | ﹤0.01% | 5949 |
|
|
2021
Q2 | $319K | Buy |
60,339
+56,761
| +1,586% | +$294K | ﹤0.01% | 5761 |
|
|
2021
Q1 | $17K | Sell |
3,578
-200
| -5% | -$1.04K | ﹤0.01% | 6925 |
|
|
2020
Q4 | $16K | Buy |
3,778
+595
| +19% | +$2.55K | ﹤0.01% | 6644 |
|
|
2020
Q3 | $13K | Sell |
3,183
-132
| -4% | -$511 | ﹤0.01% | 6394 |
|
|
2020
Q2 | $8K | Sell |
3,315
-153,539
| -98% | -$451K | ﹤0.01% | 6501 |
|
|
2020
Q1 | $453K | Sell |
156,854
-18,659
| -11% | -$83.6K | ﹤0.01% | 4572 |
|
|
2019
Q4 | $664K | Sell |
175,513
-68,871
| -28% | -$330K | ﹤0.01% | 4808 |
|
|
2019
Q3 | $1.25M | Buy |
244,384
+136
| +0.1% | +$840 | ﹤0.01% | 4396 |
|
|
2019
Q2 | $1.51M | Buy |
244,248
+8,248
| +3% | +$47.5K | ﹤0.01% | 4264 |
|
|
2019
Q1 | $1.68M | Buy |
236,000
+18,014
| +8% | +$162K | ﹤0.01% | 4124 |
|
|
2018
Q4 | $1.86M | Buy |
217,986
+109,989
| +102% | +$1.43M | ﹤0.01% | 3905 |
|
|
2018
Q3 | $2.16M | Sell |
107,997
-27,937
| -21% | -$656K | ﹤0.01% | 3913 |
|
|
2018
Q2 | $3.51M | Buy |
135,934
+64,733
| +91% | +$1.79M | ﹤0.01% | 3488 |
|
|
2018
Q1 | $1.7M | Buy |
71,201
+12,612
| +22% | +$398K | ﹤0.01% | 4000 |
|
|
2017
Q4 | $1.99M | Sell |
58,589
-1,209
| -2% | -$33.8K | ﹤0.01% | 3952 |
|
|
2017
Q3 | $1.27M | Buy |
59,798
+55,671
| +1,349% | +$1.02M | ﹤0.01% | 4350 |
|
|
2017
Q2 | $72K | Sell |
4,127
-645
| -14% | -$10.7K | ﹤0.01% | 5736 |
|
|
2017
Q1 | $84K | Buy |
4,772
+1,685
| +55% | +$28.7K | ﹤0.01% | 5696 |
|
|
2016
Q4 | $52K | Buy |
3,087
+2,261
| +274% | +$35K | ﹤0.01% | 5912 |
|
|
2016
Q3 | $14K | Sell |
826
-1,435
| -63% | -$21.8K | ﹤0.01% | 6272 |
|
|
2016
Q2 | $34K | Buy |
+2,261
| New | +$37.3K | ﹤0.01% | 6015 |
|
|
2016
Q1 | – | Sell |
-3,319
| Closed | -$94K | – | 7450 |
|
|
2015
Q4 | $94K | Buy |
+3,319
| New | +$55.9K | ﹤0.01% | 5755 |
|
|
2015
Q3 | – | Sell |
-33
| Closed | -$1K | – | 7511 |
|
|
2015
Q2 | $1K | Buy |
33
+23
| +230% | +$447 | ﹤0.01% | 7162 |
|
|
2015
Q1 | $0 | Sell |
10
-790
| -99% | -$13.5K | ﹤0.01% | 7731 |
|
|
2014
Q4 | $14K | Buy |
+800
| New | +$12.1K | ﹤0.01% | 6944 |
|
Bank of America's ADMS Position: Q4 2021 in Review
Bank of America sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 66,745 shares — an estimated $328K sold.
Bank of America first reported a position in ADMS in Q4 2014 and held it in 26 quarters. The position peaked at $3.51M in Q2 2018. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.
- Bank of America reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- Bank of America sold 66,745 Adamas Pharmaceuticals shares in Q4 2021, an estimated $328K.
- Bank of America first reported a position in Adamas Pharmaceuticals in Q4 2014 and held it in 26 quarters.
- Bank of America's Adamas Pharmaceuticals position peaked at $3.51M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.
Based on Bank of America's 13F filing for Q4 2021, filed 8 Feb 2022.